Your browser doesn't support javascript.
loading
Impact of ultrasound-guided high-intensity focused ultrasound for the treatment of uterine fibroids on ovarian reserve and quality of life: a single-center prospective cohort study.
Gu, Wei; Yuan, Jiangjing; Zhou, Yun; Li, Yuhong; Wang, Yudong.
Afiliación
  • Gu W; Department of Gynecologic Oncology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
  • Yuan J; Shanghai Municipal Key Clinical Specialty, Shanghai, China.
  • Zhou Y; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
  • Li Y; Department of Gynecologic Oncology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
  • Wang Y; Shanghai Municipal Key Clinical Specialty, Shanghai, China.
BMC Womens Health ; 24(1): 470, 2024 Aug 24.
Article en En | MEDLINE | ID: mdl-39182055
ABSTRACT

BACKGROUND:

We aimed to evaluate changes in ovarian reserve and quality of life in women treated with ultrasound-guided high-intensity focused ultrasound (USgHIFU) for uterine fibroids.

METHODS:

In this single-center prospective study, a total of 69 patients with uterine fibroids treated with USgHIFU from October 2018 to November 2021 were enrolled. Fibroid volume, anti-Müllerian hormone (AMH) levels, uterine fibroid symptom scores, and uterine fibroid symptoms and quality of life (UFS-QOL) questionnaire scores before and 1, 3, and 6 months after USgHIFU treatment were analyzed. Correlations between AMH levels and age, fibroid type, and fibroid location were assessed.

RESULTS:

Data from 54 of the 69 patients included in the present study were analyzed. The UFS-QOL scores at baseline and at 1 month and 6 months after USgHIFU treatment were 70 (50.75-87.50), 57 (44.75-80.00), and 52 (40.75-69.00) points, respectively (p < 0.001). The rate of fibroid volume reduction increased significantly at the 3-month follow-up compared with the 1-month follow-up (p < 0.001), and no significant change was observed between the 3-month and 6-month follow-ups (p > 0.99). The median AMH levels before and at 1, 3 and 6 months after treatment were 1.22 (0.16-3.28) ng/ml, 1.12 (0.18-2.52) ng/ml, 1.15 (0.19-2.08) ng/ml and 1.18 (0.36-2.43) ng/ml, respectively (p = 0.2). Multivariate linear regression analyses revealed that age was independently associated with AMH levels.

CONCLUSIONS:

USgHIFU treatment for uterine fibroids can significantly improve quality of life with minimal adverse effects on ovarian function.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Uterinas / Hormona Antimülleriana / Reserva Ovárica / Leiomioma Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: BMC Womens Health Asunto de la revista: SAUDE DA MULHER Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Uterinas / Hormona Antimülleriana / Reserva Ovárica / Leiomioma Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: BMC Womens Health Asunto de la revista: SAUDE DA MULHER Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido